Achieve Life Sciences, Inc.ACHVNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

globenewswire.com

Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026

SEATTLE and VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its fourth quarter and full year 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday, March 24, 2026, at 8:30 AM EDT. To access the webcast, please use the following link: 4Q25 Earnings Webcast.

defenseworld.net

Achieve Life Sciences (NASDAQ:ACHV) Share Price Crosses Above 200 Day Moving Average – Time to Sell?

Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) shares passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $4.24 and traded as high as $4.37. Achieve Life Sciences shares last traded at $4.14, with a volume of 530,131 shares changing hands. Analyst Ratings Changes

globenewswire.com

Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study

A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new data showing that 6 and 12 weeks of cytisinicline delivers meaningful quitting success, regardless of participants' prior use of smoking cessation medications or number of previous quit attempts. Achieve also announces late-breaking survey data from ORCA-OL, demonstrating participant experience with extended cytisinicline use.

defenseworld.net

Achieve Life Sciences (ACHV) Expected to Announce Earnings on Tuesday

Achieve Life Sciences (NASDAQ: ACHV - Get Free Report) will likely be announcing its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Interested persons are encouraged to explore the company's upcoming Q4 2025 earning overview page for the latest

defenseworld.net

Achieve Life Sciences (NASDAQ:ACHV) Shares Pass Above 200 Day Moving Average – What’s Next?

Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $4.11 and traded as high as $4.55. Achieve Life Sciences shares last traded at $4.39, with a volume of 430,401 shares changing hands. Wall Street Analyst Weigh

defenseworld.net

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a

seekingalpha.com

Achieve Life Sciences: A Binary Bet With Cytisinicline And A Potential 2026 Launch

Achieve Life Sciences is a single-asset microcap centered on cytisinicline, with an accepted NDA and a June 20, 2026, PDUFA. Cytisinicline's α4β2 partial agonism aims to reduce cravings and blunt nicotine reward. In fact, the most promising aspect of cytisinicline was that its Phase 3 ORCA trials showed strong quit-rate deltas versus placebo.

seekingalpha.com

Achieve Life Sciences: Could Be The Best 'Tobacco' Stock For 2026 - Strong Buy

Achieve Life Sciences is a late-stage Pharma company awaiting FDA approval for Cytisinicline, a novel (though proven) smoking cessation therapy, with a decision expected in June. Cytisinicline demonstrates superior efficacy and safety versus current treatments, with strong precedent in Europe and a large, underserved U.S. market. ACHV's market cap (~$250M) is a fraction of its potential, with peak sales for smoking and vaping cessation possibly reaching $2–3 billion.

globenewswire.com

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced that effective January 28, 2026, Achieve's board of directors approved stock option grants to purchase an aggregate of 115,000 shares of its common stock for five new employees under Achieve's 2024 Equity Inducement Plan. The stock options have an exercise price equal to the closing price of Achieve's common stock on January 28, 2026.

globenewswire.com

Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

SEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that it has confirmed the promotion of Mark Rubinstein, M.D., from Interim Chief Medical Officer to Chief Medical Officer (CMO).

defenseworld.net

Achieve Life Sciences (NASDAQ:ACHV) Share Price Crosses Above 200-Day Moving Average – Here’s Why

Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $3.58 and traded as high as $5.21. Achieve Life Sciences shares last traded at $4.99, with a volume of 732,134 shares

defenseworld.net

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above Two Hundred Day Moving Average – Time to Sell?

Shares of Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) crossed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $3.48 and traded as high as $4.39. Achieve Life Sciences shares last traded at $4.32, with a volume of 585,831 shares.

prnewswire.com

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

SEATTLE and VANCOUVER, BC , Dec. 17, 2025 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, announced today that the company will be hosting in-person one-on-one meetings coinciding with the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026.

defenseworld.net

Achieve Life Sciences (NASDAQ:ACHV) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) shares passed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $3.44 and traded as high as $4.82. Achieve Life Sciences shares last traded at $4.69, with a volume of 391,516 shares. Wall

globenewswire.com

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced that the company has issued inducement grants of stock options to Erik Atkisson, Chief Legal Officer, and other new employees.

defenseworld.net

Head-To-Head Survey: Achieve Life Sciences (NASDAQ:ACHV) vs. Carisma Therapeutics (NASDAQ:CARM)

Carisma Therapeutics (NASDAQ: CARM - Get Free Report) and Achieve Life Sciences (NASDAQ: ACHV - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk. Analyst Recommendations This is a breakdown

defenseworld.net

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Crosses Above 200-Day Moving Average – Here’s Why

Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $3.24 and traded as high as $4.45. Achieve Life Sciences shares last traded at $4.32, with a volume of 390,366 shares. Analyst Upgrades and Downgrades ACHV has

seekingalpha.com

Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript

Achieve Life Sciences, Inc. ( ACHV ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Nicole Jones Richard A. Stewart - CEO & Executive Director Jaime Xinos - Chief Commercial Officer Mark Oki - Chief Financial Officer Jerry Wan - VP of Finance & Principal Accounting Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Brandon Folkes - H.C.

globenewswire.com

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner's National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025

globenewswire.com

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully Concluded DSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance